Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H50O2 |
| Molecular Weight | 454.7275 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](\C=C\[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)OC(C)=O)C(C)C
InChI
InChIKey=IZEUIYYDWBKERE-ZRODXFKISA-N
InChI=1S/C31H50O2/c1-8-23(20(2)3)10-9-21(4)27-13-14-28-26-12-11-24-19-25(33-22(5)32)15-17-30(24,6)29(26)16-18-31(27,28)7/h9-11,20-21,23,25-29H,8,12-19H2,1-7H3/b10-9+/t21-,23-,25+,26+,27-,28+,29+,30+,31-/m1/s1
| Molecular Formula | C31H50O2 |
| Molecular Weight | 454.7275 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: O75469|||Q9UJ26 Gene ID: 8856.0 Gene Symbol: NR1I2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17622954 |
|||
Target ID: Q96RI1 Gene ID: 9971.0 Gene Symbol: NR1H4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17622954 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Demonstration of biological activities of extracts from Isodon rugosus Wall. Ex Benth: Separation and identification of bioactive phytoconstituents by GC-MS analysis in the ethyl acetate extract. | 2017-05-30 |
|
| Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. | 2007-09 |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17622954
Cells, transfected with retinoic X receptor (RXR), hRXR alpha , were treated with agonist or agonist plus 10 uM stigmasterol acetate (StigAc) and 24 h later harvested and processed, and luciferase activities normalized as before. The agonist ligandsused were FXR, CDCA(100 uM); pregnane X receptor (PXR), peroxisome proliferator-activated receptor gamma (PPAR gamma), rosiglitazone(1 uM). Increasing concentrations of StigAc (0–10 uM) suppress CDCA-activated FXR with an IC50 of 5–10 uM, which is well below the physiologic range of Stig levels found in the serum of patients with serological evidence of PNAC. In addition to suppressing CDCA-activated FXR-LBD activity, StigAc also suppresses ligand-activated PXR-LBD activity. Except for a slight increase in RXR alpha LBD activity, StigAc has no discernible effect on any other NRLBD tested.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:59 GMT 2025
by
admin
on
Mon Mar 31 17:48:59 GMT 2025
|
| Record UNII |
P5M1K7SCX9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6437330
Created by
admin on Mon Mar 31 17:48:59 GMT 2025 , Edited by admin on Mon Mar 31 17:48:59 GMT 2025
|
PRIMARY | |||
|
225-082-7
Created by
admin on Mon Mar 31 17:48:59 GMT 2025 , Edited by admin on Mon Mar 31 17:48:59 GMT 2025
|
PRIMARY | |||
|
P5M1K7SCX9
Created by
admin on Mon Mar 31 17:48:59 GMT 2025 , Edited by admin on Mon Mar 31 17:48:59 GMT 2025
|
PRIMARY | |||
|
8109
Created by
admin on Mon Mar 31 17:48:59 GMT 2025 , Edited by admin on Mon Mar 31 17:48:59 GMT 2025
|
PRIMARY | |||
|
69434
Created by
admin on Mon Mar 31 17:48:59 GMT 2025 , Edited by admin on Mon Mar 31 17:48:59 GMT 2025
|
PRIMARY | |||
|
DTXSID301315192
Created by
admin on Mon Mar 31 17:48:59 GMT 2025 , Edited by admin on Mon Mar 31 17:48:59 GMT 2025
|
PRIMARY | |||
|
4651-48-3
Created by
admin on Mon Mar 31 17:48:59 GMT 2025 , Edited by admin on Mon Mar 31 17:48:59 GMT 2025
|
PRIMARY |